转移性去势抵抗性前列腺癌不良预后与恩扎卢胺耐药的基因组驱动因素
该研究对101例转移性去势抵抗性前列腺癌(mCRPC)患者进行全基因组测序和全转录组RNA测序,分析驱动基因改变与总生存(OS)的关联,并以无偏方式识别恩扎卢胺耐药的基因组驱动因素。结果显示RB1双DNA改变独立预测不良OS(中位14.1 vs 42.0个月;p=0.007),Wnt/β-catenin通路在恩扎卢胺耐药患者中富集,β-catenin突变仅见于耐药患者(p=0.01)并独立预测不良OS(中位13.6 vs 41.7个月;p=0.025)。
要点
- RB1双DNA改变独立预测mCRPC患者不良OS(中位14.1 vs 42.0个月;p=0.007)。
- Wnt/β-catenin通路是恩扎卢胺耐药患者中差异调节最显著的通路。
- β-catenin突变仅见于恩扎卢胺耐药患者(p=0.01),并独立预测不良OS(中位13.6 vs 41.7个月;p=0.025)。
核心结论
- 全基因组测序分析发现的RB1双DNA改变独立与mCRPC患者不良OS相关。
- Wnt/β-catenin通路在恩扎卢胺耐药中起重要作用,耐药患者该通路差异表达且β-catenin突变富集。
- β-catenin突变在本队列中预测不良OS。
研究设计与样本
- 对101例mCRPC患者队列的全基因组测序和RNA测序结果进行生存分析和基因集富集分析(GSEA)。
- OS为所有单变量和多变量生存分析的临床终点。
- 以无偏方式识别恩扎卢胺耐药的候选驱动因素,并用Fisher精确检验评估顶级候选基因突变在恩扎卢胺耐药患者中的富集。
主要发现
- 携带RB1双DNA改变的患者中位OS为14.1个月,无此改变者为42.0个月(p=0.007)。
- GSEA显示Wnt/β-catenin通路是恩扎卢胺耐药患者中差异调节最显著的通路。
- β-catenin突变仅见于恩扎卢胺耐药患者(p=0.01),携带者中位OS为13.6个月,非携带者为41.7个月(p=0.025)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metastatic castration-resistant prostate cancer (mCRPC) is the lethal form of the disease. Several recent studies have identified genomic alterations in mCRPC, but the clinical implications of these genomic alterations have not been fully elucidated. OBJECTIVE: To use whole-genome sequencing (WGS) to assess the association between key driver gene alterations and overall survival (OS), and to use whole-transcriptome RNA sequencing to identify genomic drivers of enzalutamide resistance. DESIGN, SETTING, AND PARTICIPANTS: We performed survival analyses and gene set enrichment analysis (GSEA) on WGS and RNA sequencing results for a cohort of 101 mCRPC patients. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: OS was the clinical endpoint for all univariate and multivariable survival analyses. Candidate drivers of enzalutamide resistance were identified in an unbiased manner, and mutations of the top candidate were further assessed for enrichment among enzalutamide-resistant patients using Fisher's exact test. RESULTS AND LIMITATIONS: Harboring two DNA alterations in RB1 was independently predictive of poor OS (median 14.1 vs 42.0mo; p=0.007) for men with mCRPC. GSEA identified the Wnt/β-catenin pathway as the top differentially modulated pathway among enzalutamide-resistant patients. Furthermore, β-catenin mutations were exclusive to enzalutamide-resistant patients (p=0.01) and independently predictive of poor OS (median 13.6 vs 41.7mo; p=0.025). CONCLUSIONS: The presence of two RB1 DNA alterations identified in our WGS analysis was independently associated with poor OS among men with mCRPC. The Wnt/β-catenin pathway plays an important role in enzalutamide resistance, with differential pathway expression and enrichment of β-catenin mutations in enzalutamide-resistant patients. Moreover, β-catenin mutations were predictive of poor OS in our cohort. PATIENT SUMMARY: We observed a correlation between genomic findings for biopsy samples from metastases from men with metastatic castration-resistant prostate cancer (mCRPC) and clinical outcomes. This work sheds new light on clinically relevant genomic alterations in mCRPC and provides a roadmap for the development of new personalized treatment regimens in mCRPC.
引用
- Chen WS, Aggarwal R, Zhang L, et al. Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2019. PMID: 30928160. doi:10.1016/j.eururo.2019.03.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。